Skip to main content
Clinical Trials/NCT01245933
NCT01245933
Completed
Not Applicable

Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD

Philipps University Marburg Medical Center22 sites in 1 country2,741 target enrollmentNovember 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Sponsor
Philipps University Marburg Medical Center
Enrollment
2741
Locations
22
Primary Endpoint
Change from baseline in BODE-Score at 18 months
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to determine the prevalence and severity of extrapulmonary disorders and to quantify the impact of extrapulmonary organ manifestations on morbidity and mortality of COPD patients.

Furthermore the investigators evaluate the relationship between systemic inflammation and organ involvement.

Detailed Description

Chronic diseases and comorbidities have an increasing impact on individual life and health care use, as exemplified in chronic obstructive pulmonary disease (COPD). Currently, independent, comprehensive databases allowing for an integrated view are lacking. The study will for the first time establish a large, comprehensive longitudinal database covering a broad panel of comorbidities an markers of systemic alterations. These data will be of unique value in revealing specific phenotypes of COPD via patterns and risk profiles of comorbidities, enabling a more precise diagnosis and targeting of therapy, and an efficient allocation of resources.

Registry
clinicaltrials.gov
Start Date
November 2010
End Date
December 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Claus Vogelmeier

Prof. Dr.

Philipps University Marburg Medical Center

Eligibility Criteria

Inclusion Criteria

  • aged 40 years and older
  • diagnosis of COPD (GOLD-Criteria) or chronic bronchitis
  • informed consent
  • available for repeated study visits pver 18 months

Exclusion Criteria

  • having undergone big lung surgery (e.g. lung reduction, lung transplant)
  • Moderate or severe exacerbation within the last 4 weeks
  • having a lung tumor
  • Unable to walk or to understand the intention of the project

Outcomes

Primary Outcomes

Change from baseline in BODE-Score at 18 months

Time Frame: at initial visite, after 18, 36, 54, 72, 90 and 108 months

The BODE-Score comprises BMI, airway obstruction, dyspnea and exercise capacity and is a good predictor for death in COPD patients. Progression is defined as a change in BODE-score by \>=1 point over the observation period.

Secondary Outcomes

  • COPD related hospitalization(after 18, 36, 54, 72, 90 and 108 months)
  • COPD related mortality(after 18 months)

Study Sites (22)

Loading locations...

Similar Trials